

STUDENTS CORNER

Student's Drug Updates Session-National Pharmacology Conference 2014,
Pharmacological Trends 21st Century. Slides of winner # 1.

Safia Anwar


UPDATE ON IBUPROFEN



SAFIA ANWAR
BDS-05
BUMDC





INTRODUCTION:




INDOMETHACIN



IBUPROFEN



CONVENTIONAL USES:



UPDATE:

**IBUPROFEN IS
PREFERRED OVER
INDOMETHACIN FOR
THE TREATMENT OF
PATENT DUCTUS
ARTERIOSUS**



SOURCE

Website: Pubmed.com

Date of Publish: Jan 13, 2013

Date of Access: May 24, 2014

PATENT DUCTUS ARTERIOSUS ?

- Congenital Heart disorder
- Small opening or pathway between the pulmonary and aortic



INDOMETHACIN VS IBUPROFEN

EFFECTS	INDOMETHACIN	IBUPROFEN
Non COX Pathway	Yes	No
GI PERFORATIONS	Yes	No
NECROTIZING ENTEROCOLITIS	Yes	Slight
RENAL FAILURE	Yes	No

INDOMETHACIN VS IBUPROFEN: MOA

Indomethacin

- ▶ Nonselective COX inhibitor (particularly COX-1)
- ▶ Inhibits other Non-COX pathways which inhibit cerebral, renal and mesenteric blood flow which adds to its deleterious effect

Ibuprofen

- ▶ Reversible Non-selective COX inhibitor
- ▶ **No effect on Non-COX pathways** hence safer

CONCLUSION:

IBUPROFEN is a better drug in comparison to INDOMETHACIN for treating PDA and is also a more safer drug

